Leading the charge

Led by a mission-driven team, Innoviva Specialty Therapeutics blends rigorous medical science with the latest in pharmaceutical innovation

Executive Team

Pavel Raifeld, CFA

Chief Executive Officer

Pavel brings deep financial and strategic expertise from experiences at Sarissa Capital Management, Credit Suisse’s healthcare investment banking, and biopharmaceutical consulting at McKinsey & Company and BCG. He holds a BA from Harvard and an MBA from Columbia University.

Marianne Zhen

Chief Accounting Officer

Joining Innoviva in 2014, Marianne previously served as Corporate Controller for three tech companies. A member of the AICPA and the CalCPA, she also served on the CalCPA Peninsula Silicon Valley Chapter board. Marianne holds a BS in Business Administration from San Francisco State University.

Matt Ronsheim, PhD

Chief Technical Officer

Dr. Ronsheim has led teams in development, CMC, and supply chain across various formulations and disease areas at Enanta Pharmaceuticals, Merck/Cubist, and Forest Laboratories. He holds a BS from Southern Connecticut State University and a PhD in Synthetic Organic Chemistry from the University of New Hampshire.

Christine Coyne

Chief Commercial Officer

Before joining Innoviva, Christine was CCO at SCYNEXIS and held leadership roles at Paratek. She has also led marketing and sales teams at Wyeth-Ayerst Global Pharmaceuticals, Endo, and Auxilium Pharmaceuticals. She holds a BA from West Chester University and an MBA from Eastern University.

Steve Basso, Chief Financial Officer

Steve Basso

Chief Financial Officer

Mr. Basso brings more than 30 years of experience of financial leadership, primarily in the pharmaceutical industry. Prior to joining Innoviva, Mr. Basso served as the Chief Financial Officer and Chief Operating Officer at Cybrexa Therapeutics and has held a variety of financial leadership positions at Inozyme Pharma, Alexion Pharmaceuticals and Pfizer. He received a BS in business from Providence College and an MBA from Boston College.

Margaret Koziel, Chief Medical Officer

Margaret Koziel, MD

Chief Medical Officer

Dr. Koziel joined us in 2023 from Axcella Therapeutics, where she was Chief Medical Officer. She has previous leadership roles at Novartis Institutes for Biomedical Research, Vertex and Kaleido. She was also a Professor of Medicine, having positions at Harvard Medical School and the University of Massachusetts, with over 90 publications in leading peer reviewed journals. She has a BA and MD from Dartmouth.


Join a team where all colleagues can do their best work while making a lasting impact.

Learn More